Skip to content

Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life

Research output: Contribution to journalReview article

Original languageEnglish
Article number177
Number of pages7
JournalFrontiers in Cardiovascular Medicine
DateAccepted/In press - 14 Nov 2019
DatePublished (current) - 27 Nov 2019


Cardiovascular regenerative medicine is an exciting new approach that promises to change the current care of million people world-wide. Major emphasis was given to the quality and quantities of regenerative products, but recent evidence points to the importance of a better specification of the target population that may take advantage of these advanced medical treatments. Patient stratification is an important step in drug development. Tailoring treatment to the patient's specificity allowed significant improvement in cancer therapy, but personalized regenerative medicine is still at the initial stage in the cardiovascular field. For example, new-borns with a congenital heart condition and elderly people require dedicated therapeutic approaches, which adapt to their lifetime needs. In these people, personalized treatments may overcome the benefits delivered by standard protocols. In this review, we provide insights into these extreme stages of life as potential targets for cardiovascular reconstitution.

    Research areas

  • aging, regenerative, cardiovascular, stratification, personalized medicine, congenital heart disease, bone marrow, frailty

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Frontiers at Please refer to any applicable terms of use of the publisher.

    Final published version, 790 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups